Previous publication indicates that AXL mRNA overexpression has been associated with imatinib and nilotinib resistant CML and therefore this gene alteration could be a potential biomarker to predict TKI treatment failure [22]. Here, AXL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.